The lack of correlation between inhibition of aggregation and cAMP levels with canine platelets.
Arachidonic acid (AA) induced aggregation of canine platelets can be inhibited by various phosphodiesterase inhibitors (PDIs) with the order of potency IBMX greater than or equal to papaverine greater than Ro 20-1724 greater than theophylline. With aggregation induced by AA plus epinephrine (EPI), only IBMX and papaverine inhibited at 100 microM. None of these PDIs affected the basal cAMP levels but all potentiated the PGE1-stimulated cAMP production, with the order of potency being Ro 20-1724 greater than papaverine greater than IBMX greater than theophylline. PGE1 at 1 microM caused a sharp increase in cAMP and complete inhibition of platelet aggregation induced by AA plus EPI. However, when EPI was added before PGE1, there was no elevation of cAMP yet inhibition of aggregation still occurred. Our results indicated that inhibition of platelet aggregation does not require a measurable increase in cAMP.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000527:Alprostadil; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood*; D003864:Depression, Chemical; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D008297:Male; D010208:Papaverine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011458:Prostaglandins E / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology
D001095:Arachidonic Acids; D010726:Phosphodiesterase Inhibitors; D011458:Prostaglandins E; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D000527:Alprostadil; D015056:1-Methyl-3-isobutylxanthine; D004837:Epinephrine